
|Videos|January 16, 2014
The Immunogenic Potential of Biosimilars: Should Health Care Providers Be Concerned?
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
Advertisement
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
3
Q&A: Making Plant-Based Eating Practical in Pharmacy-Led Cardiometabolic Care
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5


























